Robert J. Gray, PhD, has been affiliated with the organization as a statistical leader since 2000. His major research activities involve the design and analysis of clinical trials and the study of related statistical issues. Under Dr. Gray’s leadership of the ECOG-ACRIN Biostatistics and Data Management Center, located at the Dana-Farber Cancer Institute, the organization is annually involved in the design and analysis of dozens of cancer clinical trials in most adult malignancies. One notable example is TAILORx, the ground-breaking cancer clinical trial that defined which women with early breast cancer may or may not benefit from chemotherapy when guided by the use of the Oncotype DX® Breast Recurrence Score, a genomic test. Another is NCI-MATCH, the largest precision medicine cancer trial.
Dr. Gray is a professor of biostatistics at Harvard University and the Dana-Farber Cancer Institute in Boston. He received his PhD in Statistics from Oregon State University in 1982. He has been a member of the faculty at Harvard University since 1984 and a tenured professor since 2003. He is Chair of the Committee of Group Statisticians for the National Cancer Institute (NCI) since 2003. He maintains active membership in the NCI Breast Cancer Steering Committee and the Breast Cancer Intergroup Correlative Science Committee.
Dr. Gray first became part of the Group in 1982 as a clinical trials statistician working primarily with the Breast Cancer Committee. At that time, it was the Eastern Cooperative Oncology Group (ECOG). When ECOG merged with the American College of Radiology Imaging Network (ACRIN) in 2012 to form the ECOG-ACRIN Cancer Research Group, Dr. Gray became a Group Statistician.
|Scientific Planning and Review|
|Biostatistics and Data Management|
|Active Clinical Trials|
|Find a Participating Institution|